This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.This study is designed to offer extension of treatment to all patients with RRMS who completed full treatment in the double-blind, randomized, parallel group, multicenter Study 307000A, and to further assess the safety and tolerability of Betaseron 500 mcg QOD and 250 mcg QOD in these patients.
Showing the most recent 10 out of 426 publications